AML is an aggressive and mortal disease. Worldwide, approximately 120.000 new AML cases and over 100.000 AML-related deaths occur each year and FLT3 mutations contribute to poor prognosis in AML. FLT3 mutations of 149 patients aged 20-95 years who were diagnosed with AML in our clinic were evaluated retrospectively. Relapse/refractory disease was found in 87.2% of these cases and FLT3 mutation in 25.5%. Of mutation-positive cases 65.8% had FLT3-ITD mutation and 34.2% had FLT3-TKD mutation. In our study, 38 patients with newly diagnosed FLT3 mutations were treated with FLT3 inhibitors such as midostaurin, sorafenib, and sunitinib in combination with chemotherapy and 76.3% (n:29) of the patients with FLT3 mutation received midostaurin. Mortality rate was higher in those with FLT3-TKD mutation compared to those with FLT3-ITD mutation. The risk of mortality in patients who received midostaurin and chemotherapy was 2.0 times higher than the control group, which consisted mostly of relapsed/refractory patients who received only chemotherapy. The cumulative mortality rate in all patients was 66.4%, with a median OS of 44.8 months. Increasing age (HR: 1.03; p